These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 10511123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
    Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y.
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):417-27. PubMed ID: 12652111
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
    Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J.
    J Cardiovasc Pharmacol; 2000 Sep; 36(3):351-60. PubMed ID: 10975593
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
    Nagakura N, Saeki T, Harada K, Yoshitake S, Kobayashi S, Yamanaka T, Saito I.
    Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.
    Sun B, Le SN, Lin S, Fong M, Guertin M, Liu Y, Tandon NN, Yoshitake M, Kambayashi J.
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):577-85. PubMed ID: 12352320
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels.
    Lindgren SH, Andersson TL, Vinge E, Andersson KE.
    Acta Physiol Scand; 1990 Oct; 140(2):209-19. PubMed ID: 2176433
    [Abstract] [Full Text] [Related]

  • 13. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
    Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H.
    Pharmacology; 1988 Oct; 36(5):313-20. PubMed ID: 2841693
    [Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.
    Hanson MS, Stephenson AH, Bowles EA, Sridharan M, Adderley S, Sprague RS.
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H786-93. PubMed ID: 18586889
    [Abstract] [Full Text] [Related]

  • 15. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
    Nakamura K, Ikomi F, Ohhashi T.
    J Vasc Res; 2006 Aug; 43(1):86-94. PubMed ID: 16286783
    [Abstract] [Full Text] [Related]

  • 16. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
    Zhang W, Colman RW.
    Blood; 2007 Sep 01; 110(5):1475-82. PubMed ID: 17392505
    [Abstract] [Full Text] [Related]

  • 17. Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta1- and beta2-adrenergic receptor activation in human myocardium.
    Carceles MD, Fuentes T, Aroca V, Lopez J, Hernández J.
    Clin Ther; 2007 Aug 01; 29(8):1718-24. PubMed ID: 17919552
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The pharmacology of cilostazol.
    Schrör K.
    Diabetes Obes Metab; 2002 Mar 01; 4 Suppl 2():S14-9. PubMed ID: 12180353
    [Abstract] [Full Text] [Related]

  • 20. Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.
    Yagi H, Yamaguchi N, Shida Y, Hayakawa M, Matsumoto M, Sugimoto M, Wada H, Tsubaki K, Fujimura Y.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):151-5. PubMed ID: 22796451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.